PTEN and prostate carcinoma: As is the AMPK/mTOR pathway, IKK/NF-κB signaling is constitutively active in prostate cancer due to dysregulation/activation of oncogenic pathways such as Akt or loss of PTEN tumor-suppressor function [52].